Video

Gil Melmed, MD: Biologics for Inflammatory Bowel Disease

Author(s):

On June 3, 2021, Gil Melmed, MD, led an HCPLive State of the Science expert webinar on the current and future state of inflammatory bowel disease (IBD).

Melmed, Director of Inflammatory Bowel Disease Clinical Research at Cedars-Sinai, was joined by his Cedars-Sinai colleagues Christina Ha, MD, Dermot McGovern, MD, PhD, and Gaurav Syal, MD for a 90-minute program on the following topics:

  • IBD and COVID-19: What have we learned?
  • Biologics for IBD – when, which one, and in whom?
  • Algorithms of Care for IBD
  • Emerging Therapies – the future is bright!

In the clip above, Melmed joins HCPLive for a recap interview on the subjects of the program, highlighting current biologic therapy options for IBD, and what future clinical research should entail.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.